Researchers report that weight-loss injections such as Ozempic and Mounjaro could slow age-related biological decline that contributes to earlier death in women. The coverage says a new study finds benefits when treatment begins around the age of 62.
The outlets describe the work as linking these drugs to reduced “body damage” associated with aging, potentially translating into longer lifespan. Both reports frame the findings as coming from modelled or study-based estimates rather than confirmed outcomes in large, long-term real-world trials. They do not present details in the shared text about the study design, participant numbers, duration, or how the lifespan projections are calculated.
While both sources highlight the same potential timing and class of medication, their emphasis is on the possible magnitude of benefit—reported as extending life by about a decade—rather than discussing risks, eligibility, or the need for further evidence.
